According to the preliminary figures, slightly more than 95 percent of the B shares offered have been subscribed through the exercise of subscription rights. In addition, new B shares corresponding to 25 percent of the total number of shares offered have been subscribed without the support of subscription rights, meaning that the new share issue is oversubscribed. As a consequence of the oversubscription of the new share issue, no new B shares will be allocated to MGA Holding AB in its role as guarantor.
Active Biotech's new share issue will be completed according to the following timetable:
Press release on final subscription level for new share issue
Approximately May 30
Notification of any allocation of shares not supported by subscription rights
Approximately May 26
Payment for shares allocated through subscription not supported by subscription rights
Approximately May 28
First day of trading in new B shares
Approximately June 4
Lund, May 19, 2003
Active Biotech AB (publ)
Sven Andréasson
President & CEO
For further information about Active Biotech visit http://activebiotech.com.
Active Biotech
AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
E-mail info@activebiotech.com